Israel Biotech Fund (IBF) invests exclusively in Israeli and Israeli related biotech companies at all development stages. Having started its activity in late 2015, the fund has a rich portfolio with more than 16 portfolio companies at various development stages from different fields as well as significant partnerships with key market players. The fund is committed to seeking high-value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotechnology companies. IBF provides its portfolio companies with hands-on guidance and the necessary resources for long-term sustainable growth. Along with its team, the fund has a group of more than 30 leading pharmaceutical and financial executives acting as advisors to the fund and its portfolio.